ALK and non-small cell lung carcinoma: ALK (anaplastic lymphoma kinase) inhibitors Crizotinib, Alectinib, Entrectinib, Lorlatinib, Brigatinib, and Ceritinib are all FDA-approved as single agent treatments in non-small-cell lung cancers that are positive for ALK rearrangements (22) (also see https://www.targetedonc.com/view/bazhenova-compares-frontline-alk-inhibitors-for-alk-nsclc).